Factors affecting the outcome of stem cell transplantation from unrelated donors for childhood acute lymphoblastic leukemia in third remission.

abstract：:HLA-C matching is an important determinant of outcome after myeloablative unrelated donor (URD) hematopoietic stem cell transplantation. However, its importance in non-myeloablative stem cell transplantation (NST) is not known. We report a retrospective analysis of 111 patients who underwent URD NST, of whom 78 were 1...

journal_title：Bone marrow transplantation

authors： Ho VT,Kim HT,Liney D,Milford E,Gribben J,Cutler C,Lee SJ,Antin JH,Soiffer RJ,Alyea EP

更新日期：2006-05-01 00:00:00

abstract：:Seventeen patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) were treated with the ICE regimen plus G-CSF with the aim of mobilizing and collecting Ph-negative peripheral stem cells (PSC) in the setting of an autotransplant program. Fifteen patients had CML in first chronic phase (CP), ...

journal_title：Bone marrow transplantation

authors： Boqué C,Petit J,Sarrá J,Cancelas JA,Muñoz J,Español JI,de la Banda E,Aventin A,Berlanga J,Ferrá C,Amill B,Torrico C,Azqueta C,Llucià M,García J,Grañena A

更新日期：1996-11-01 00:00:00

abstract：:Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regime...

journal_title：Bone marrow transplantation

authors： Tageja N,Korde N,Kazandjian D,Panch S,Manasanch E,Bhutani M,Kwok M,Mailankody S,Yuan C,Stetler-Stevenson M,Leitman SF,Sportes C,Landgren O

更新日期：2018-11-01 00:00:00

abstract：:Six hundred and fifteen centers from 45 countries reported a total 30,293 HSCT to this 2008 EBMT survey with 26,810 first transplants (40% allogeneic, 60% autologous). This corresponds to an increase of 7% for the allogeneic and 3% for the autologous HSCT. Main indications were leukemias (32%; 89% allogeneic); lymphom...

journal_title：Bone marrow transplantation

authors： Gratwohl A,Baldomero H,Schwendener A,Gratwohl M,Apperley J,Frauendorfer K,Niederwieser D

更新日期：2011-02-01 00:00:00

abstract：:Eighteen patients with chronic myelogenous leukemia (CML) in chronic (9 patients) or advanced phases (9 patients) underwent autologous bone marrow transplantation (BMT) with a preparative regimen using high doses of cyclophosphamide, etoposide and total body irradiation (CY-VP16-TBI): cyclophosphamide 60 mg/kg daily o...

journal_title：Bone marrow transplantation

authors： Kantarjian HM,Talpaz M,Andersson B,Khouri I,Giralt S,Rios MB,Champlin R,Hester J,Deisseroth AB

更新日期：1994-07-01 00:00:00

abstract：:We retrospectively assessed the outcome and pretransplantation predictors of the outcome in 118 patients aged ≥ 50 years who received fludarabine-containing reduced-intensity allo-SCT (RIST) for B-cell ALL in the first or second CR. Eighty patients received transplants from unrelated donors. Seventy-eight patients wer...

journal_title：Bone marrow transplantation

authors： Kanamori H,Mizuta S,Kako S,Kato H,Nishiwaki S,Imai K,Shigematsu A,Nakamae H,Tanaka M,Ikegame K,Yujiri T,Fukuda T,Minagawa K,Eto T,Nagamura-Inoue T,Morishima Y,Suzuki R,Sakamaki H,Tanaka J

更新日期：2013-11-01 00:00:00

abstract：:Seventy-nine patients with AML in CR1 received allo-SCT between May 2006 and May 2011, and the prognostic impact of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) mutation was evaluated in the context of other clinical prognostic factors. Patients with FLT3/ITD + AML had significantly inferior DFS (...

journal_title：Bone marrow transplantation

authors： Sengsayadeth SM,Jagasia M,Engelhardt BG,Kassim A,Strickland SA,Goodman S,Lucid C,Vnencak-Jones CL,Greer JP,Savani BN

更新日期：2012-12-01 00:00:00

abstract：:Several approaches have been developed to overcome historical barriers associated with poor outcomes in the setting of HLA-haploidentical allogeneic transplantation (HaploSCT). Here, we examine the outcome of patients with various hematological disorders undergoing HaploSCT with high-dose, post-transplantation cycloph...

journal_title：Bone marrow transplantation

authors： Fayard A,Daguenet E,Blaise D,Chevallier P,Labussière H,Berceanu A,Yakoub-Agha I,Socié G,Charbonnier A,Suarez F,Huynh A,Mercier M,Bulabois CE,Lioure B,Chantepie S,Beguin Y,Bourhis JH,Malfuson JV,Clément L,Peffault de

更新日期：2019-10-01 00:00:00

abstract：:Hematopoietic cell transplantation (HCT) has become an established standard of care for many older patients with hematologic malignancies. The effect of transplantation on the quality of life (QOL) of older patients, however, has not been well studied. We thus analyzed QOL in patients ⩾60 undergoing an allogeneic HCT ...

journal_title：Bone marrow transplantation

authors： Hamilton BK,Rybicki L,Dabney J,McLellan L,Haddad H,Foster L,Abounader D,Kalaycio M,Sobecks R,Dean R,Duong H,Hill BT,Bolwell BJ,Copelan EA

更新日期：2014-11-01 00:00:00

abstract：:Among 42 consecutive recipients of unrelated marrow were 39 HLA-A, -B, -DR identical, matched unrelated donors (MUD) and three with one HLA antigen mismatch. The majority were genomically typed for DRB, DQA, DQB and DPB. The recipients of MUD marrow were compared with 39 recipients of marrow from HLA-identical sibling...

journal_title：Bone marrow transplantation

authors： Ringdén O,Remberger M,Persson U,Ljungman P,Aldener A,Andström E,Aschan J,Bolme P,Dahllöf G,Dalianis T

更新日期：1995-04-01 00:00:00

abstract：:Although intensive therapy with autologous bone marrow transplantation (ABMT) has improved the outcome of advanced neuroblastoma, nearly half the patients with this disease still relapse after a single ABMT. In our previous study, 10 of 22 patients relapsed within 16 months post-transplantation. Predictive risk-factor...

journal_title：Bone marrow transplantation

authors： Kawa-Ha K,Yumura-Yagi K,Inoue M,Park DY,Okamura T,Yasui M,Oota H,Sakata N,Yoneda M,Imura K

更新日期：1996-06-01 00:00:00

abstract：:We investigated the use of 'prophylactic' donor lymphocyte infusions (DLI) containing 1 x 107 CD3+ cells, given at 30, 60 and 90 days post-allogeneic blood and marrow transplantation (BMT), following conditioning with fludarabine 30 mg/m(2)/4 days and melphalan 70 mg/m(2)/2 days. GVHD prophylaxis consisted of cyclospo...

journal_title：Bone marrow transplantation

authors： de Lima M,Bonamino M,Vasconcelos Z,Colares M,Diamond H,Zalcberg I,Tavares R,Lerner D,Byington R,Bouzas L,da Matta J,Andrade C,Carvalho L,Pires V,Barone B,Maciel C,Tabak D

更新日期：2001-01-01 00:00:00

abstract：:We retrospectively compared the incidence of acute graft-versus-host disease (GVHD) before and after September 1999, when we changed the mode of cyclosporine A (CsA) administration from twice-daily infusions (TD) (n=58) to continuous infusion (CIF) (n=71). The incidence of grade II-IV acute GVHD in the CIF group (56%)...

journal_title：Bone marrow transplantation

authors： Ogawa N,Kanda Y,Matsubara M,Asano Y,Nakagawa M,Sakata-Yanagimoto M,Kandabashi K,Izutsu K,Imai Y,Hangaishi A,Kurokawa M,Tsujino S,Ogawa S,Aoki K,Chiba S,Motokura T,Hirai H

更新日期：2004-03-01 00:00:00

abstract：:Information regarding the chimeric status of hematopoietic stem cell transplantation (HSCT) recipients is of great significance when comparing different conditioning and prophylactic therapies. In recent years, short tandem repeats/variable number tandem repeats (STRs/VNTRs) have emerged as the best tool for chimerism...

journal_title：Bone marrow transplantation

authors： Talwar S,Khan F,Nityanand S,Agrawal S

更新日期：2007-05-01 00:00:00

abstract：:Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recover...

journal_title：Bone marrow transplantation

authors： Platzbecker U,Thiede C,Freiberg-Richter J,Röllig C,Helwig A,Schäkel U,Mohr B,Schaich M,Ehninger G,Bornhäuser M

更新日期：2001-03-01 00:00:00

abstract：:Quality of life (QOL) is increasingly recognized as an important clinical outcome of hematopoietic cell transplantation (HCT), but patient education is often overlooked. The aim of the current qualitative study was to examine education regarding post-HCT QOL from the patient's perspective. Allogeneic HCT recipients pa...

journal_title：Bone marrow transplantation

authors： Jim HS,Quinn GP,Gwede CK,Cases MG,Barata A,Cessna J,Christie J,Gonzalez L,Koskan A,Pidala J

更新日期：2014-02-01 00:00:00

abstract：:Fetus-to-fetus transplantation has been suggested for the treatment of hemoglobinopathies in utero. However, dissimilar results have to date been obtained by different groups. We describe a case in which fetus-to-fetus transplantation in HLA-identical twins was performed at the 19th week of gestation by infusion of 0....

journal_title：Bone marrow transplantation

authors： Orlandi F,Giambona A,Messana F,Marino M,Abate I,Calzolari R,Damiani F,Jakil C,Renda M,Dieli F,Buscemi F,Westgren M,Ringden O,Maggio A

更新日期：1996-09-01 00:00:00

abstract：:Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from ...

journal_title：Bone marrow transplantation

authors： Jedlickova Z,Schmid C,Koenecke C,Hertenstein B,Baurmann H,Schwerdtfeger R,Tischer J,Kolb HJ,Schleuning M

更新日期：2016-05-01 00:00:00

abstract：:In the current study, we evaluated a combination of tacrolimus and mycophenolate mofetil (MMF) as GvHD prophylaxis in 50 patients undergoing truly nonmyeloablative (NM; 90 mg/m(2) fludarabine, 2 Gy TBI) hematopoietic SCT (HSCT) from unrelated donors. Median patient age was 51 years (range, 25-67 years). After a median...

journal_title：Bone marrow transplantation

authors： Zohren F,Schroeder T,Czibere A,Fenk R,Bruns I,Kondakci M,Saure C,Haas R,Kobbe G

更新日期：2011-05-01 00:00:00

abstract：:Thirty patients with relapsed pediatric solid tumors received high-dose carboplatin and etoposide with autologous marrow support in a dose-escalation trial. These patients had received extensive prior treatment, which included both cisplatin and etoposide in 25 cases. Six patient cohorts received carboplatin in doses ...

journal_title：Bone marrow transplantation

authors： Santana VM,Schell MJ,Williams R,Bowman LC,Thompson EI,Brenner MK,Mirro J Jr

更新日期：1992-11-01 00:00:00

abstract：:Our growing physiological understanding of hematopoietic progenitor cells has led to the clinical use of circulating progenitor cells, including stem cells, for either reconstitution of hematopoietic function, up to the transduction of functional genes into a self-renewing cell system. In the following, an attempt has...

journal_title：Bone marrow transplantation

authors： Körbling M,Fliedner TM

更新日期：1996-05-01 00:00:00

abstract：:One hundred and ninety-three patients with hematological malignancies and a follow-up > or =1 year, treated with stem cell transplantation (45 autologous, 99 allogeneic T cell-depleted matched, 49 allogeneic T cell-depleted mismatched) from July 1985 to May 1998, were considered evaluable for the development of catara...

journal_title：Bone marrow transplantation

authors： Aristei C,Alessandro M,Santucci A,Aversa F,Tabillo A,Carotti A,Latini RA,Cagini C,Latini P

更新日期：2002-03-01 00:00:00

abstract：:A patient with malignant lymphoma, large cell type and extensive bone marrow necrosis at presentation is reported. Bone marrow necrosis persisted even after a complete remission was induced with standard chemotherapy. Because of this adverse prognostic factor, circulating stem cells were collected and reinfused follow...

journal_title：Bone marrow transplantation

authors： Khan AM,Yamase H,Tutschka PJ,Bilgrami S

更新日期：1997-05-01 00:00:00

abstract：:Identifying risk factors that lead to graft failure may reduce morbidity and mortality after bone marrow transplantation (BMT) for hematologic malignancies. We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an...

journal_title：Bone marrow transplantation

authors： Schultz KR,Ratanatharathorn V,Abella E,Eisenbrey AB,Karanes C,Lum LG,de Planque MM,Uberti JP,Ravindranath Y,Sensenbrenner LL

更新日期：1994-06-01 00:00:00

abstract：:The feasibility of transplantation using highly purified G-CSF-mobilized peripheral blood CD34+ cells from HLA-identical sibling donors without prophylactic post-transplant immunosuppression was prospectively studied in 10 adult first chronic phase chronic myeloid leukemia (CML) patients with special reference to graf...

journal_title：Bone marrow transplantation

authors： Beelen DW,Peceny R,Elmaagacli A,Ottinger H,Kummer G,Opalka B,Seeber S,Schaefer UW

更新日期：2000-10-01 00:00:00

abstract：:Diarrhea in marrow transplant recipients is a frequent complication attributable to non-infectious events such as acute GVHD or infectious events such as viral gastroenteritis. Rotavirus and enteric adenovirus are the most frequent viral pathogens. To determine the frequency of these infections, we prospectively exami...

journal_title：Bone marrow transplantation

authors： Troussard X,Bauduer F,Gallet E,Freymuth F,Boutard P,Ballet JJ,Reman O,Leporrier M

更新日期：1993-12-01 00:00:00

abstract：:As a consequence of the significantly larger inoculum of lymphoid cells present in peripheral blood stem cell (PBSC) harvests compared to bone marrow (BM), it is possible that autoPBSCT recipients may have an earlier and*or enhanced response to vaccines. Until data to confirm this become available, the European Blood ...

journal_title：Bone marrow transplantation

authors： Gandhi MK,Egner W,Sizer L,Inman I,Zambon M,Craig JI,Marcus RE

更新日期：2001-10-01 00:00:00

abstract：:High relapse rates during the first year after autologous stem cell transplantation (ASCT) for multiple myeloma or non-Hodgkin lymphoma are due to the failure of high-dose chemotherapy to eradicate minimal residual disease. Post-ASCT immunorecovery studies have shown that quantities of natural killer (NK) cells return...

journal_title：Bone marrow transplantation

authors： Porrata LF,Inwards DJ,Lacy MQ,Markovic SN

更新日期：2001-10-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (alloHSCT) has become a well-established treatment option for many patients suffering from malignant and non-malignant diseases. In the past decade, high-resolution HLA-typing, remission surveillance, pre-emptive immune intervention, and standardisation in supportive ...

journal_title：Bone marrow transplantation

authors： Bakhtiar S,Salzmann-Manrique E,Hutter M,Krenn T,Duerken M,Faber J,Reinhard H,Kreyenberg H,Huenecke S,Cappel C,Bremm M,Pfirrmann V,Merker M,Barnbrock A,Schöning S,Willasch AM,Rettinger E,Soerensen J,Klingebiel TE,Jar

更新日期：2019-05-01 00:00:00

abstract：:We report a case of unexplained graft failure in a 33-year-old man who received an allogeneic bone marrow graft that contained a donor-recipient mismatch involving the highly immunogenic NA1 neutrophil-specific alloantigen system. Laboratory and clinical data suggest that an alloimmune process related to the neutrophi...

journal_title：Bone marrow transplantation

authors： Klumpp TR,Herman JH,Mangan KF,Macdonald JS

更新日期：1993-03-01 00:00:00